Pulse Biosciences Receives Downgrade to Sell Rating

Pulse Biosciences (NASDAQ:PLSE) was recently downgraded by analysts at StockNews.com, who assigned it a "sell" rating in a report released on Monday.

Pulse Biosciences alerts:

Pulse Biosciences Stock Performance

On Monday, shares of Pulse Biosciences declined by $0.51, closing at $16.09. A total of 459,987 shares changed hands, significantly higher than the average trading volume of 198,258. The company's fifty-day simple moving average stands at $18.78, while its 200-day moving average is $18.15. Over the past year, Pulse Biosciences has experienced a low of $6.60 and a high of $25.00.

Institutional Trading Activity

Several hedge funds have recently modified their positions in PLSE. Invesco Ltd. drastically increased its stake in Pulse Biosciences by 1,956.7% during the fourth quarter. Following the purchase of an additional 204,061 shares, Invesco now holds 214,490 shares, valued at approximately $3,734,000. Similarly, Vanguard Group Inc. raised its holdings by 15.1% in the fourth quarter, owning 1,146,339 shares now valued at $19,958,000 after acquiring 150,506 additional shares. Charles Schwab Investment Management Inc. boosted its position by 193.0% during the third quarter, owning 148,114 shares worth around $2,598,000 after purchasing an additional 97,565 shares. Furthermore, State Street Corp increased its stake by 17.8% in the same quarter, bringing its total to 461,333 shares valued at $8,092,000 after buying an extra 69,696 shares last quarter. Additionally, Panoramic Capital LLC entered a new position in Pulse Biosciences during the fourth quarter, valued at approximately $846,000. Notably, institutional investors hold 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc. operates in the bioelectric medicine sector, providing innovative technology through its CellFX System. This platform is software-enabled and delivers nanosecond electrical pulses to selectively clear targeted cells without damaging adjacent healthy tissue, utilizing Nano-Pulse Stimulation technology for various medical applications.

Considerations for Investors

Before making any investment decisions regarding Pulse Biosciences, it’s essential for investors to gather information from reputable analysts who track the stock. Presently, the company holds a Hold rating, but analysts have identified five other stocks as preferable investment options.

Stocks, Investors, Analysis